The Prophylactic and Therapeutic Efficacy of the Broadly Active Antiviral Ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a Mouse Model of Lethal Ebola Virus Infection
Bluemling, G. R.; Mao, S.; Natchus, M. G.; Painter, W.; Mulangu, S.; Lockwood, M.; De La Rosa, A. D. L. R.; Brasel, T.; Comer, J. E.; Freiberg, A. N.; Kolykhalov, A.; Painter, G. R.
Show abstract
The unprecedented magnitude of the 2013-2016 Ebola virus (EBOV) epidemic in West Africa resulted in over 11,000 deaths and spurred an international public health emergency. A second outbreak in 2018-2020 in DRC resulted in an additional >3400 cases and nearly 2300 deaths (WHO Disease Outbreak News: Update 26 June, 2020). These large outbreaks across geographically diverse regions highlight the need for the development of effective oral therapeutic agents that can be easily distributed for self-administration to populations with active disease or at risk of infection. Herein, we report the in vivo efficacy of N4-hydroxycytidine (EIDD-1931), a broadly active ribonucleoside analog and the active metabolite of the prodrug EIDD-2801 (molnupiravir), in murine models of lethal EBOV infection. Twice daily oral dosing with EIDD-1931 at 200 mg/kg for 7 days, initiated either with a prophylactic dose 2 hours before infection, or as therapeutic treatment starting 6 hours post-infection, resulted in 92-100% survival of mice challenged with lethal doses of EBOV, reduced clinical signs of Ebola virus disease (EVD), reduced serum virus titers, and facilitated weight loss recovery. These results support further investigation of molnupiravir as a potential therapeutic or prophylactic treatment for EVD.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- High titers of infectious SARS-CoV-2 in COVID-19 corpses 91%
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 90%
- Enhanced surveillance of monkeypox in Bas-Uele, Democratic Republic of Congo: the limitations of symptom-based case definitions. 90%
Similar papers in this journal
- Compound FC-10696 Inhibits Egress and Spread of Marburg Virus 95%
- Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants 94%
- Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity 93%
Similar papers in this journal
- Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2 94%
- Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus. 94%
- A pigtailed macaque model for Kyasanur Forest disease virus and Alkhurma hemorrhagic disease virus 94%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.